Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models

Aberrant activation in fibroblast growth factor signaling has been implicated in the development of various cancers, including squamous cell lung cancer, squamous cell head and neck carcinoma, colorectal and bladder cancer. Thus, fibroblast growth factor receptors (FGFRs) present promising targets f...

Descripción completa

Detalles Bibliográficos
Autores principales: Grünewald, Sylvia, Politz, Oliver, Bender, Sebastian, Héroult, Mélanie, Lustig, Klemens, Thuss, Uwe, Kneip, Christoph, Kopitz, Charlotte, Zopf, Dieter, Collin, Marie‐Pierre, Boemer, Ulf, Ince, Stuart, Ellinghaus, Peter, Mumberg, Dominik, Hess‐Stumpp, Holger, Ziegelbauer, Karl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Cancer Therapy and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6766871/
https://www.ncbi.nlm.nih.gov/pubmed/30807645
http://dx.doi.org/10.1002/ijc.32224

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6766871/
https://www.ncbi.nlm.nih.gov/pubmed/30807645
http://dx.doi.org/10.1002/ijc.32224

Ejemplares similares